1 unchanged sentence
10b5-1 Trading Arrangements and Non-Rule 10b5-1 Trading Arrangements
−Removed: the fiscal quarter ended September 30, 2025, none of our officers or directors, as those terms are defined in Rule 16a-1(f), adopted
−Removed: or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as those terms
−Removed: are defined in Item 408 of Regulation S-K.
+Added: the fiscal quarter ended March 31, 2026, none of our officers or directors, as those terms are defined in Rule 16a-1(f), adopted or terminated
+Added: a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as those terms are defined in
+Added: Item 408 of Regulation S-K.
the Exhibit Index following the signature page to this Quarterly Report on Form 10-Q for a list of exhibits filed or furnished with this
2 unchanged sentences
the undersigned thereunto duly authorized.
−Removed: MATINAS BIOPHARMA HOLDINGS, INC.
−Removed: November 10, 2025
−Removed: Chief Executive Officer (Principal Executive Officer)
−Removed: November 10, 2025
−Removed: Chief Financial Officer
−Removed: (Principal Financial and Accounting Officer)
+Added: BIOPHARMA HOLDINGS, INC.
+Added: Chief Executive Officer, President & Interim Chief Financial Officer
+Added: Executive Officer and Principal Financial and Accounting Officer)
Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to Amendment No.
2 unchanged sentences
1 to the Company’s Registration Statement on Form S-1 filed with the SEC on February 7, 2014).
−Removed: Certificate of Amendment, dated October 29, 2015 to Certificate of Incorporation.
−Removed: (incorporated herein by reference to the Company’s Current Report on Form 8-K filed with the SEC on November 5, 2015).
−Removed: Certificate of Amendment of Certificate of Incorporation, dated August 30, 2024 (filed as an exhibit to the Current Report on Form 8-K, filed with the Commission on September 3, 2024 and incorporated herein by reference).
−Removed: Form of Certificate of Designation of Series C Convertible Preferred Stock (filed as an exhibit to the Current Report on Form 8-K filed with the Commission on February 13, 2025 and incorporated herein by reference).
−Removed: Certificate of Amendment of Certificate of Incorporation, as amended, of Matinas BioPharma Holdings, Inc., dated August 6, 2025 (filed as an exhibit to the Current Report on Form 8-K filed with the Commission on August 6, 2025 and incorporated herein by reference).
−Removed: Form of Common Stock Purchase Warrant, dated April 5, 2024 (incorporated herein by reference to the Company’s Current Report on Form 8-K filed with the SEC on April 5, 2024).
−Removed: Description of Securities (filed as an exhibit to the Annual Report on Form 10-K filed with the Commission on April 15, 2025 and incorporated herein by reference).
−Removed: Form of Common Stock Purchase Warrant (filed as an exhibit to the Current Report on Form 8-K filed with the Commission on February 13, 2025 and incorporated herein by reference).
−Removed: Form of Warrant Exchange Agreement, dated August 15, 2025 (filed as an exhibit to the Current Report on Form 8-K filed with the Commission on August 18, 2025 and incorporated herein by reference).
−Removed: Certification of Chief Executive Officer
−Removed: Certification of Chief Financial Officer
−Removed: Section 1350 Certifications
−Removed: Inline XBRL Instance Document.
−Removed: Inline XBRL Taxonomy Extension
−Removed: Schema Document.
−Removed: Inline XBRL Taxonomy Extension
−Removed: Calculation Linkbase Document.
−Removed: Inline XBRL Taxonomy Extension
−Removed: Definition Linkbase Document.
−Removed: Inline XBRL Taxonomy Extension
−Removed: Label Linkbase Document.
−Removed: Inline XBRL Taxonomy Extension
−Removed: Presentation Linkbase Document.
−Removed: Cover Page Interactive
−Removed: Data File (embedded within the Inline XBRL document)
+Added: Certificate of Amendment of Certificate of Incorporation, dated October 29, 2015 .
+Added: (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on November 5, 2015).
+Added: Certificate of Amendment of Certificate of Incorporation, dated August 30, 2024 (incorporated by reference to Exhibit 3.1 the Company’s Current Report on Form 8-K filed with the SEC on September 3, 2024).
+Added: Form of Certificate of Designation of Series C Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on February 13, 2025).
+Added: Amendment No.
+Added: 1 to the Bylaws (incorporated by reference to Exhibit 3.1 the Company’s Current Report on Form 8-K filed with the SEC on May 2, 2025).
+Added: Certificate of Amendment of Certificate of Incorporation, dated August 6, 2025 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on August 6, 2025).
+Added: Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
+Added: Section 1350 Certification
+Added: XBRL Instance Document.
+Added: XBRL Taxonomy Extension Schema Document.
+Added: XBRL Taxonomy Extension Calculation Linkbase Document.
+Added: XBRL Taxonomy Extension Definition Linkbase Document.
+Added: XBRL Taxonomy Extension Label Linkbase Document.
+Added: XBRL Taxonomy Extension Presentation Linkbase Document.
+Added: Page Interactive Data File (embedded within the Inline XBRL document)
Filed herewith.
−Removed: Indicates a management contract or compensation plan, contract or arrangement.
−Removed: Certain portions of this exhibit, that are not material
−Removed: and would likely cause competitive harm to the registrant if publicly disclosed, have been redacted pursuant to Item 601(b)(10) of Regulation
+Added: information in this exhibit is furnished and deemed not filed with the SEC for purposes of section 18 of the Exchange Act of 1934, as
+Added: amended, and is not to be incorporated by reference into any filing of Matinas BioPharma Holdings, Inc.
+Added: under the Securities Act or the
+Added: Exchange Act of whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.